A comprehensive development agenda on tenofovir alafenamide in clinical practice

A Di Biagio, N Riccardi, S Rusconi, G Guaraldi, M Borderi, A De Luca, N Gianotti, S Lo Caputo, P Maggi, R Maserati, F Maggiolo

Research output: Contribution to journalArticle

Abstract

The introduction of tenofovir (TFV) alafenamide (TAF) into clinical practice will be a further revolution in antiretroviral therapy. Currently available HIV-1 regimens are wide enough to allow diversified usage in different settings. Despite the fact that TAF is not capillary accessible, even in industrialized countries, ultimate International Guidelines have already included TAF in backbone or in single-tablet regimens. Due to a better safety profile, TAF will progressively replace TFV disoproxil fumarate, both in naïve and experienced patients. However, therapeutic innovations have to deal with budget constraints and different global spending-review patterns. The aim of this article is to give a comprehensive agenda of TAF use in naïve and experienced HIV-1 infected patients, providing a full review of the studies present in the literature and contextualizing these findings into daily clinical practice. © 2018, Publicaciones Permanyer. All rights reserved.
Original languageEnglish
Pages (from-to)75-82
Number of pages8
JournalAIDS Reviews
Volume20
Issue number2
Publication statusPublished - 2018

Fingerprint

Tenofovir
HIV-1
Budgets
Developed Countries
Tablets
Guidelines
Safety
Therapeutics
GS-7340

Cite this

Di Biagio, A., Riccardi, N., Rusconi, S., Guaraldi, G., Borderi, M., De Luca, A., ... Maggiolo, F. (2018). A comprehensive development agenda on tenofovir alafenamide in clinical practice. AIDS Reviews, 20(2), 75-82.

A comprehensive development agenda on tenofovir alafenamide in clinical practice. / Di Biagio, A; Riccardi, N; Rusconi, S; Guaraldi, G; Borderi, M; De Luca, A; Gianotti, N; Lo Caputo, S; Maggi, P; Maserati, R; Maggiolo, F.

In: AIDS Reviews, Vol. 20, No. 2, 2018, p. 75-82.

Research output: Contribution to journalArticle

Di Biagio, A, Riccardi, N, Rusconi, S, Guaraldi, G, Borderi, M, De Luca, A, Gianotti, N, Lo Caputo, S, Maggi, P, Maserati, R & Maggiolo, F 2018, 'A comprehensive development agenda on tenofovir alafenamide in clinical practice', AIDS Reviews, vol. 20, no. 2, pp. 75-82.
Di Biagio A, Riccardi N, Rusconi S, Guaraldi G, Borderi M, De Luca A et al. A comprehensive development agenda on tenofovir alafenamide in clinical practice. AIDS Reviews. 2018;20(2):75-82.
Di Biagio, A ; Riccardi, N ; Rusconi, S ; Guaraldi, G ; Borderi, M ; De Luca, A ; Gianotti, N ; Lo Caputo, S ; Maggi, P ; Maserati, R ; Maggiolo, F. / A comprehensive development agenda on tenofovir alafenamide in clinical practice. In: AIDS Reviews. 2018 ; Vol. 20, No. 2. pp. 75-82.
@article{657df169dcfd432a8cd04b41ec8b0f29,
title = "A comprehensive development agenda on tenofovir alafenamide in clinical practice",
abstract = "The introduction of tenofovir (TFV) alafenamide (TAF) into clinical practice will be a further revolution in antiretroviral therapy. Currently available HIV-1 regimens are wide enough to allow diversified usage in different settings. Despite the fact that TAF is not capillary accessible, even in industrialized countries, ultimate International Guidelines have already included TAF in backbone or in single-tablet regimens. Due to a better safety profile, TAF will progressively replace TFV disoproxil fumarate, both in na{\"i}ve and experienced patients. However, therapeutic innovations have to deal with budget constraints and different global spending-review patterns. The aim of this article is to give a comprehensive agenda of TAF use in na{\"i}ve and experienced HIV-1 infected patients, providing a full review of the studies present in the literature and contextualizing these findings into daily clinical practice. {\circledC} 2018, Publicaciones Permanyer. All rights reserved.",
author = "{Di Biagio}, A and N Riccardi and S Rusconi and G Guaraldi and M Borderi and {De Luca}, A and N Gianotti and {Lo Caputo}, S and P Maggi and R Maserati and F Maggiolo",
year = "2018",
language = "English",
volume = "20",
pages = "75--82",
journal = "AIDS Reviews",
issn = "1139-6121",
publisher = "Publicaciones Permanyer",
number = "2",

}

TY - JOUR

T1 - A comprehensive development agenda on tenofovir alafenamide in clinical practice

AU - Di Biagio, A

AU - Riccardi, N

AU - Rusconi, S

AU - Guaraldi, G

AU - Borderi, M

AU - De Luca, A

AU - Gianotti, N

AU - Lo Caputo, S

AU - Maggi, P

AU - Maserati, R

AU - Maggiolo, F

PY - 2018

Y1 - 2018

N2 - The introduction of tenofovir (TFV) alafenamide (TAF) into clinical practice will be a further revolution in antiretroviral therapy. Currently available HIV-1 regimens are wide enough to allow diversified usage in different settings. Despite the fact that TAF is not capillary accessible, even in industrialized countries, ultimate International Guidelines have already included TAF in backbone or in single-tablet regimens. Due to a better safety profile, TAF will progressively replace TFV disoproxil fumarate, both in naïve and experienced patients. However, therapeutic innovations have to deal with budget constraints and different global spending-review patterns. The aim of this article is to give a comprehensive agenda of TAF use in naïve and experienced HIV-1 infected patients, providing a full review of the studies present in the literature and contextualizing these findings into daily clinical practice. © 2018, Publicaciones Permanyer. All rights reserved.

AB - The introduction of tenofovir (TFV) alafenamide (TAF) into clinical practice will be a further revolution in antiretroviral therapy. Currently available HIV-1 regimens are wide enough to allow diversified usage in different settings. Despite the fact that TAF is not capillary accessible, even in industrialized countries, ultimate International Guidelines have already included TAF in backbone or in single-tablet regimens. Due to a better safety profile, TAF will progressively replace TFV disoproxil fumarate, both in naïve and experienced patients. However, therapeutic innovations have to deal with budget constraints and different global spending-review patterns. The aim of this article is to give a comprehensive agenda of TAF use in naïve and experienced HIV-1 infected patients, providing a full review of the studies present in the literature and contextualizing these findings into daily clinical practice. © 2018, Publicaciones Permanyer. All rights reserved.

M3 - Article

VL - 20

SP - 75

EP - 82

JO - AIDS Reviews

JF - AIDS Reviews

SN - 1139-6121

IS - 2

ER -